TrialThe Lancet. Oncology2014

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Jan A Burger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.